华兰生物：关于参股公司收到药物临床试验批准通知书的公告

Core Viewpoint - Hualan Biological announced that its subsidiary, Hualan Ankang Biological Co., Ltd., received approval from the National Medical Products Administration for clinical trials of the biosimilar drug, Pembrolizumab injection, targeting multiple cancers [2] Group 1 - The approved indications for Pembrolizumab include melanoma, non-small cell lung cancer, esophageal cancer, and head and neck squamous cell carcinoma [2]